display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced mGC or mGEJC
mGC or mGEJC - L2 - all population
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab alone
Ipilimumab (10 mg/kg) CA184-162
anti-PD-(L)1
avelumab based treatment
avelumab alone JAVELIN Gastric 300
nivolumab based treatment
nivolumab alone ATTRACTION-2 ...
pembrolizumab based treatment
pembrolizumab alone KEYNOTE-061 ...

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons